

Identity:

Title: Prof. MD PhD

Family Name(s): Schiattarella

First Name(s): Gabriele G.

Age: 39

Photo:**Application for the following position in the HFA Board or Nominating Committee:**

Ordinary Board member

Place of work

If you work in multiple places, please provide the one where you spend the most time or that you consider to be your main place of practice.

Institute/organisation:	Charité – Universitätsmedizin Berlin
Department:	Deutsches Herzzentrum der Charité / Max Rubner Center (MRC) for Cardiovascular-Metabolic-Renal Research
Address:	Hessische Str. 4a
Post code / Zip:	10115
Country:	Germany

General Curriculum Vitae (500 words max)

Please also include your H index and top 5 to 10 publications in the last 5 years

Education and Board Certifications:

- PhD in Clinical and Experimental Medicine with highest honors, Federico II University, Naples, Italy
- Specialization in Cardiology with highest score, Federico II University, Naples, Italy
- MD Medicine Degree with highest honors, Federico II University, Naples, Italy

Current Positions:

- Group leader, Max Rubner Center (MRC), Charité University Medical Center, Berlin, Germany
- Guest Group Leader, Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany

Honors and Awards (Selection):

- Outstanding Investigator Award, International Society of Heart Research (ISHR)
- European Research Council (ERC) Starting grant
- Finalist, Melvin Marcus Early Career Investigator Award, American Heart Association (AHA)
- Keynote Lecture on HFpEF, German Cardiac Society (DGK)
- “Richard J. Bing” Investigator Award, International Society of Heart Research (ISHR)
- Deputy Spokesperson of the DFG Collaborative Research Centre 1470

Grant Review (Selection):

- UK Research and Innovation (UKRI), UK
- European Research Council (ERC), European Union
- Swiss National Science Foundation (SNF), Switzerland
- Dutch Heart Foundation (Hartstichting), the Netherlands
- British Heart Foundation (BHF), UK (2022)

Reviewer for Scientific Journals (Selection):

- The Lancet, JACC, Circulation Research, Cardiovascular Research, Nature Metabolism, Nature Cardiovascular Research, Nature Review Cardiology, Science Advances, and others

Editorial Positions (Selection):

- Associate Editor of “Circulation”
- Editorial board member of “Circulation Research”

- Editorial board member of “Cardiovascular Research”

Organization of Scientific Meetings (Selection):

- Organizer of Keystone Symposia “Trajectories to Heart Failure: Immunometabolic Mechanisms”
- Organizer of international meeting “HFpEF: Bridging Disciplines”
- Organizer inaugural symposium of the Max Rubner Center (MRC) for Cardiovascular-Metabolic-Renal Research at Charité University

Teaching Experience (Selection):

- Co-Chair Selection Committee EMERALD International PhD Programme
- Participation in International PhD Program, Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany

Research Funding (Selection):

- Deutsche Forschungsgemeinschaft (DFG) – CRC-1470
- German Center for Cardiovascular Research (DZHK)
- European Research Council (ERC) Starting Grant
- American Heart Association (AHA)
- National Institute of Health (NIH)

Citation Metrics (source SCOPUS, February 2024):

- Number of publications: 115
- Total number of citations: 4538
- H-index: 32

List of Key Publications (Selection):

- Impaired T cell IRE1 α /XBP1 signaling directs inflammation in experimental HFpEF. Smolgovsky S, Bayer AL, et al. *J Clin Invest.* **2023.**
- Immune-mediated denervation of the pineal gland underlies sleep disturbance in cardiac disease. Ziegler KA, Ahles A, et al. *Science.* **2023.**
- Impaired AMPK signaling in HFpEF-associated Atrial Fibrillation. Tong D, Schiattarella GG, et al. *Circulation.* **2022.**
- NAD⁺ Repletion Reverses Heart Failure with Preserved Ejection Fraction. Tong D, Schiattarella GG, et al. *Circ Res.* **2021.**
- Xbp1s-FoxO1 Axis Governs Lipid Accumulation and Contractile Performance in HFpEF. Schiattarella GG, Altamirano F, et al. *Nat Commun.* **2021.**
- Female Sex Is Protective in a Preclinical Model of HFpEF. Tong D, Schiattarella GG, et al. *Circulation.* **2019.**
- Nitrosative Stress Drives Heart Failure with Preserved Ejection Fraction. Schiattarella GG, et al. *Nature.* **2019.**
- Polycystin-1 Assembles with Kv Channels to Govern Cardiomyocyte Repolarization and Contractility. Altamirano F, Schiattarella GG, et al. *Circulation.* **2019.**
- Cardiac Metabolism in HFpEF: from Fuel to Signaling. Capone F, et al. *Cardiovasc Res.* **2023**
- Immunometabolic Mechanisms of Heart Failure with Preserved Ejection Fraction. Schiattarella GG, et al. *Nat Cardiovasc Res.* **2022**

Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society

150 words maximum

Over the years, I have accumulated a wealth of experience and commitment in the cardiovascular field, demonstrated through my active roles in various committees of HFA, ESC and other major

cardiovascular societies. These engagements reflect my dedication to advancing cardiovascular sciences, fostering collaboration, and promoting diversity. I am proudly:

1. Nucleus member, "Translational Committee," HFA-ESC (2017-2022)
2. Nucleus member, "Committee on HFmrEF & HFpEF," HFA-ESC (2020-2026)
3. Nucleus member, "Committee on Pharmacology & Pharmacotherapy" - Task Force on Basic & Translational Pharmacology, HFA-ESC (2022-2026)
4. HFA Winter Meeting Program Committee (2024-2026)
5. Nucleus member and Co-coordinator, "Italian Cellular Biology Committee," Italian Society of Cardiology (2018-2026)
6. Council Member, International Society of Heart Research (ISHR-EU) (2023-2027)
7. Committee Member, "Louis N. and Arnold M. Katz" Basic Science Research Prize, American Heart Association (AHA) BCVS Committee (2023-2026)
8. Member, Gender Equality Board, DFG Collaborative Research Centre 1470 (2022-2026).

Why are you motivated to join the HFA Board or Nominating Committee?

150 words maximum

As a cardiologist-scientist, I'm eager to contribute to the HFA Board, aiming to enhance the impact of heart failure research within the ESC and beyond. My objectives include:

1. **Biomedical Advancements:** Leading collaborative efforts in cutting-edge research, identifying novel biomarkers and molecular pathways in HF, especially in HFpEF.
2. **Translational Research Integration:** Guiding the translation of findings from bench to bedside, establishing a robust translational research program. Forming alliances with clinical teams for validating novel approaches from basic research.
3. **Fundraising Innovation:** Implementing creative strategies, like virtual scientific symposia, to attract support for specific heart failure research projects. Engaging with pharmaceutical companies and governmental bodies for crucial funding.
4. **Investment in Human Resources:** Committed to developing mentorship programs, attracting top talents across Europe and globally for the HFA.

These commitments align seamlessly with the HFA's objectives, utilizing my expertise to significantly contribute to advancing heart failure understanding and treatment approaches.

How will you combine your HFA position with your daily clinical/research workload?

80 words maximum

In managing my HFA position alongside daily clinical and research tasks, I adopt a strategic and well-organized approach. My commitment to scientific progress is fueled by extensive expertise in cardiovascular medicine. Despite involvement in various societies, my focus on impactful research takes precedence. This balance is maintained through a robust support network in my research lab, administrative team, and the department of cardiology. It ensures a smooth integration of responsibilities, maximizing contributions to both the HFA and cutting-edge scientific endeavours.